Table 1.
Demographic and clinical characteristics of study population.
| D+/R+ (n = 14) | D+/R− (n = 28) | P-value | |
|---|---|---|---|
| Age in yearsa,b | 50 (19–63) | 47.5 (21–76) | NS |
| Male | 50% (7) | 68% (19) | NS |
| Cytomegalovirus (CMV) immunoglobulin G titer (AU/mL) | 47.5 (9–354) | ||
| CMV viremia | 0% | 46% (13) | <0.01 |
| Time point of CMV viremia post-kidney transplant (KT) (months) | 5 (2–12) | ||
| Renal replacement therapyb | NS | ||
| – Preemptive transplantation | 43% (6) | 43% (12) | |
| – Patients on dialysis | 57% (8) | 57% (16) | |
| Underlying kidney diseaseb | NS | ||
| – Nephrosclerosis/atherosclerosis/hypertension | 14% (2) | 25% (7) | |
| 36% (5) | 29% (8) | ||
| – Primary glomerulopathies | 21% (3) | 11% (3) | |
| – Diabetes | 3% (1) | ||
| – Urinary tract infections/stones | 3% (1) | ||
| – Reflux nephropathy | 7% (2) | ||
| – Polycystic kidney disease – Other/unknown |
29% (4) | 22% (6) | |
| Previous KTb | 1 | 1 | NS |
| Mismatches HLA class Ia | 2 (1–4) | 2 (0–4) | NS |
| Mismatches HLA class IIa | 1 (0–2) | 1 (0–2) | NS |
| Immunosuppressive medication | |||
| – Basiliximab induction therapyc | 79% (11) | 89% (25) | NS |
| – Prednisoloned | 100% (14) | 100% (28) | NS |
| – MMF | 100% (14) | 100% (28) | NS |
| – Tacrolimus | 93% (13) | 93% (26) | NS |
| – Switch tacrolimus → everolimuse | 7% (1) | 7% (2) | NS |
| Donor age in yearsa,b | 42 (27–66) | 57 (29–72) | <0.01 |
aMedian (min–max).
bAt pre-KT.
cGiven at day 0 and day 4 post-KT.
dGiven the first 3 months post-KT.
e6 months post-KT.
NS, not significant.